We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Management of chronic lymphocytic leukemia in Italy during a one year of the COVID‐19 pandemic and at the start of the vaccination program. A Campus CLL report.
- Authors
Cuneo, Antonio; Rigolin, Gian Matteo; Coscia, Marta; Quaresmini, Giulia; Scarfò, Lydia; Mauro, Francesca Romana; Motta, Marina; Quaglia, Francesca Maria; Trentin, Livio; Ferrario, Andrea; Laurenti, Luca; Reda, Gianluigi; Ferrari, Angela; Pietrasanta, Daniela; Sportoletti, Paolo; Re, Francesca; De Paoli, Lorenzo; Foglietta, Myriam; Giordano, Annamaria; Marchetti, Monia
- Abstract
Interestingly, the percentage of patients treated with chemo-immunotherapy (CIT) at the time of the COVID-19 infection did not change in the phase 1 (15%) compared to the phase 3 (15.7%), suggesting that this treatment modality maintained its role in a distinct minority of CLL patients. COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus. Keywords: chronic lymphocytic leukemia; COVID-19; targeted agents; vaccination EN chronic lymphocytic leukemia COVID-19 targeted agents vaccination 570 574 5 10/08/21 20211001 NES 211001 TRANSPARENT PEER REVIEW The peer review history for this article is available at https://publons.com/publon/10.1002/hon.2899.
- Subjects
ITALY; COVID-19 pandemic; CHRONIC lymphocytic leukemia
- Publication
Hematological Oncology, 2021, Vol 39, Issue 4, p570
- ISSN
0278-0232
- Publication type
Article
- DOI
10.1002/hon.2899